A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
Public ClinicalTrials.gov record NCT06657768. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of LY4006895 in Healthy Volunteers and Patients With Early Symptomatic AD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part.
Study identification
- NCT ID
- NCT06657768
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 128 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 45 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 28, 2024
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2027
- Last update posted
- Jun 3, 2026
2024 – 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 6
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Collaborative Neuroscience Network - CNS | Los Alamitos | California | 90720 | Recruiting |
| K2 Medical Research - The Villages | Lady Lake | Florida | 32159 | Recruiting |
| K2 Medical Research | Maitland | Florida | 32751 | Recruiting |
| Aqualane Clinical Research | Naples | Florida | 34105 | Not yet recruiting |
| Progressive Medical Research | Port Orange | Florida | 32127 | Not yet recruiting |
| K2 Medical Research - Tampa | Tampa | Florida | 33634 | Not yet recruiting |
| Atlanta Center of Medical Research | Atlanta | Georgia | 30331 | Recruiting |
| CenExel iResearch, LLC (CenExel iRA) | Decatur | Georgia | 30030 | Recruiting |
| QUEST Research Institute | Farmington Hills | Michigan | 48334 | Not yet recruiting |
| CenExel-HRI | Marlton | New Jersey | 08053 | Recruiting |
| Duke Early Phase Research Unit | Durham | North Carolina | 27710 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06657768, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06657768 live on ClinicalTrials.gov.